Kodiak Sciences (KOD) Stock Forecast: What Could Drive It in 2026
Last updated July 2026
Short answer
What is actually driving Kodiak Sciences (KOD) right now is Multi-indication Phase 3 pipeline: Kodiak is running several late-stage retinal-disease trials at once. Revenue (TTM) is ~$0 (no approved products). If that keeps playing out, the setup is favourable; the risk to it is as a pre-revenue clinical-stage biotech, Kodiak is exposed to binary trial risk, and a single failed Phase 3 readout can move the stock sharply, as the 2021 wet AMD failure demonstrated. No one can predict where KOD trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive Kodiak Sciences (KOD) higher?
1. Multi-indication Phase 3 pipeline
Kodiak is running several late-stage retinal-disease trials at once. Positive GLOW2 diabetic retinopathy results in early 2026 gave tarcocimab (Zenkuda) what the company calls a BLA-ready profile, and additional readouts (DAYBREAK in wet AMD around September 2026, PEAK in Q4 2026, PINNACLE in Q2 2027) create a series of catalysts.
2. Durability-focused ABC platform
The antibody biopolymer conjugate technology is designed to let a single injection work longer, aiming to reduce how often patients need eye injections. If durability translates into real-world dosing advantages, it could differentiate Kodiak's candidates from existing anti-VEGF standards of care.
3. Large underlying disease markets
Diabetic retinopathy, diabetic macular edema, and wet AMD affect large and growing patient populations, and the anti-VEGF category already generates multi-billion-dollar annual sales. Even a modest share of these markets would be meaningful relative to Kodiak's current size.
4. Cash to reach key readouts
Kodiak ended 2025 with roughly $210 million in cash and reported about $170 million as of March 2026, with guidance that funding lasts into 2027. That runway is intended to carry the company through its major near-term Phase 3 data events.
What could weigh on KOD?
As a pre-revenue clinical-stage biotech, Kodiak is exposed to binary trial risk, and a single failed Phase 3 readout can move the stock sharply, as the 2021 wet AMD failure demonstrated. Even positive data does not guarantee FDA approval, and a first commercial launch would face entrenched competitors including Regeneron's Eylea franchise and Roche's Vabysmo, plus lower-cost off-label and biosimilar options. The company burns cash (net loss of roughly $58 million in Q1 2026) and has stated runway only into 2027, so additional dilutive financing is a realistic possibility. Ophthalmology commercialization is capital-intensive, and durability claims must hold up in real-world use to justify premium positioning.
Where KOD trades today
A forecast starts from where the stock actually is. These are KOD's current figures, not a projection: the drivers and risks above are what would move them.
Snapshot for KOD as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
How to think about a KOD forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the KOD guide and whether KOD is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the KOD outlook
The bottom line: what is driving Kodiak Sciences (KOD) is Multi-indication Phase 3 pipeline, with revenue (ttm) at ~$0 (no approved products). If that keeps playing out the setup is favourable; the risk is as a pre-revenue clinical-stage biotech, Kodiak is exposed to binary trial risk, and a single failed Phase 3 readout can move the stock sharply, as the 2021 wet AMD failure demonstrated. No one can predict the price, so treat any KOD forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
Build a basket around KOD with Walnut
Use Kodiak Sciences as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for Kodiak Sciences (KOD)?
+
No one can reliably predict where KOD will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push Kodiak Sciences higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive KOD higher?
+
The main growth drivers are Multi-indication Phase 3 pipeline; Durability-focused ABC platform; Large underlying disease markets. Whether they play out is the real question, not a guaranteed path.
What are the risks to KOD?
+
As a pre-revenue clinical-stage biotech, Kodiak is exposed to binary trial risk, and a single failed Phase 3 readout can move the stock sharply, as the 2021 wet AMD failure demonstrated. Even positive data does not guarantee FDA approval, and a first commercial launch would face entrenched competitors including Regeneron's Eylea franchise and Roche's Vabysmo, plus lower-cost off-label and biosimilar options. The company burns cash (net loss of roughly $58 million in Q1 2026) and has stated runway only into 2027, so additional dilutive financing is a realistic possibility. Ophthalmology commercialization is capital-intensive, and durability claims must hold up in real-world use to justify premium positioning.
Will KOD stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. Kodiak Sciences's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is KOD a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the KOD "is it a buy?" page for a framework. Walnut is not an investment adviser.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.